With 17 years of experience in biosimilar, spanning both upstream and downstream process development, have a wealth of insights into optimizing production and navigating regulatory requirements. Expertise in capacity enhancement, tech transfer, process improvement, and digital transformation sounds pivotal for advancing biopharmaceutical innovation. Given extensive work with microbial and mammalian expression systems for biosimilar and bispecific antibodies, there are particular challenges or breakthroughs encountered in scaling up production or ensuring robustness in technology transfer and always eager to discuss advancements in bioprocess engineering and regulatory strategies.